FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Surg / Effect of needle diameter on the viability of equine bone ma...
Veterinary surgery : VS2017; 46(5); 731-737; doi: 10.1111/vsu.12639

Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells.

Abstract: Mesenchymal stem cells (MSCs) are frequently delivered via needle injection for treatment of musculoskeletal injuries. The purpose of this study was to evaluate the effect of needle diameter on the viability of MSCs. Methods: Equine bone marrow-derived MSCs from 5 horses were suspended in PBS, and held at room temperature for 7 hours to mimic shipping conditions. Two replicate samples for each needle size (20, 22, 23, or 25-gauge [ga]) were aspirated into a 3 mL syringe and re-injected into the holding vial 3 times, to reproduce the resuspension of cells prior to injection in clinical cases. Cells were stained with fluorescein diacetate and propidium iodide to measure viability. Flow cytometry (FC) was performed to compare cell debris and intact cells between groups. Results: MSC viability was higher when cells were passed through a 20-ga rather than a 25-ga needle. Cell suspensions passed through a 20-ga needle contained a larger percentage of intact cells, compared to 25-ga samples. The percentage of debris present in cell suspensions tended to increase with decreasing needle diameter. Neither horse nor passage had a significant effect on viability. Conclusions: Cell damage is more likely when MSCs are passed through 25-ga rather than 20-ga needles. Conclusions: Use of needles larger than 25-ga is recommended to maintain the viability of MSCs injected in horses.
© 2017 The American College of Veterinary Surgeons.
Get Full Text
Publication Date: 2017-03-22 PubMed ID: 28328147PubMed Central: PMC5493497DOI: 10.1111/vsu.12639Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research study investigates how the diameter of the needle used for injecting mesenchymal stem cells (MSCs) affects the viability of these cells. The results suggest that larger diameter needles cause less damage to MSCs, maintaining their viability during injection.

Methodology of the Research

  • The study utilized equine bone marrow-derived MSCs from 5 horses.
  • These cells were suspended in a phosphate-buffered saline (PBS) medium and were maintained at room temperature for 7 hours. This setup was designed to replicate the shipping conditions of these cells.
  • Replicate samples for different needle sizes (20, 22, 23, or 25-gauge needles) were used. Each cell suspension was aspirated into a 3 mL syringe and re-injected into the holding vial three times. This process aimed to duplicate the resuspension of the cells prior to injection in clinical cases.
  • To measure the viability of the cells, they were stained with fluorescein diacetate and propidium iodide.
  • Flow cytometry (FC) was then used to compare cell debris and intact cells among the different groups.

Results of the Research

  • The results revealed that MSCs’ viability was higher when the cells were passed through a 20-gauge needle rather than a 25-gauge needle.
  • Cell suspensions passed through a 20-gauge needle contained a larger percentage of intact cells, compared to those passed through a 25-gauge needle.
  • The research also unveiled that the percentage of debris present in the cell suspensions tended to increase as the diameter of the needle decreased.
  • The research found no significant effect on the viability of the cells concerning the horse from which the MSCs derived or the passage through which the needle was inserted.

Conclusions of the Research

  • Based on the results, the researchers concluded that a cell may suffer more damage when MSCs are passed through a 25-gauge needle as compared to a 20-gauge needle.
  • They therefore recommended the use of needles larger than 25-gauge in order to maintain the viability of MSCs that are being injected into horses.

Cite This Article

APA
Lang HM, Schnabel LV, Cassano JM, Fortier LA. (2017). Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells. Vet Surg, 46(5), 731-737. https://doi.org/10.1111/vsu.12639

Publication

Veterinary surgery : VS
ISSN: 1532-950X
NlmUniqueID: 8113214
Country: United States
Language: English
Volume: 46
Issue: 5
Pages: 731-737

Researcher Affiliations

Lang, Hayley M
  • Department of Clinical Sciences, Cornell University, Ithaca, New York.
Schnabel, Lauren V
  • Department of Clinical Sciences, Cornell University, Ithaca, New York.
Cassano, Jennifer M
  • Department of Clinical Sciences, Cornell University, Ithaca, New York.
Fortier, Lisa A
  • Department of Clinical Sciences, Cornell University, Ithaca, New York.

MeSH Terms

  • Animals
  • Bone Marrow Cells / physiology
  • Cell Culture Techniques
  • Horses
  • Mesenchymal Stem Cells / physiology
  • Needles
  • Specimen Handling / instrumentation
  • Specimen Handling / veterinary

Grant Funding

  • K08 AR060875 / NIAMS NIH HHS

Conflict of Interest Statement

. No authors have a conflict of interest.

References

This article includes 20 references
  1. Bronzini I, Patruno M, Iacopetti I, Martinello T. Influence of temperature, time and different media on mesenchymal stromal cells shipped for clinical application.. Vet J 2012 Oct;194(1):121-3.
    pubmed: 22503718doi: 10.1016/j.tvjl.2012.03.010google scholar: lookup
  2. Fortier LA. Stem cells: classifications, controversies, and clinical applications.. Vet Surg 2005 Sep-Oct;34(5):415-23.
    pubmed: 16266332doi: 10.1111/j.1532-950X.2005.00063.xgoogle scholar: lookup
  3. Fortier LA, Smith RK. Regenerative medicine for tendinous and ligamentous injuries of sport horses.. Vet Clin North Am Equine Pract 2008 Apr;24(1):191-201.
    pubmed: 18314043doi: 10.1016/j.cveq.2007.11.002google scholar: lookup
  4. Fortier LA, Travis AJ. Stem cells in veterinary medicine.. Stem Cell Res Ther 2011 Feb 23;2(1):9.
    pmc: PMC3092149pubmed: 21371354doi: 10.1186/scrt50google scholar: lookup
  5. Frisbie DD, Smith RK. Clinical update on the use of mesenchymal stem cells in equine orthopaedics.. Equine Vet J 2010 Jan;42(1):86-9.
    pubmed: 20121921doi: 10.2746/042516409X477263google scholar: lookup
  6. Schnabel LV, Fortier LA, McIlwraith CW, Nobert KM. Therapeutic use of stem cells in horses: which type, how, and when?. Vet J 2013 Sep;197(3):570-7.
    pubmed: 23778257doi: 10.1016/j.tvjl.2013.04.018google scholar: lookup
  7. Alves AG, Stewart AA, Dudhia J, Kasashima Y, Goodship AE, Smith RK. Cell-based therapies for tendon and ligament injuries.. Vet Clin North Am Equine Pract 2011 Aug;27(2):315-33.
    pubmed: 21872761doi: 10.1016/j.cveq.2011.06.001google scholar: lookup
  8. Caniglia CJ, Schramme MC, Smith RK. The effect of intralesional injection of bone marrow derived mesenchymal stem cells and bone marrow supernatant on collagen fibril size in a surgical model of equine superficial digital flexor tendonitis.. Equine Vet J 2012 Sep;44(5):587-93.
    pubmed: 22150794doi: 10.1111/j.2042-3306.2011.00514.xgoogle scholar: lookup
  9. Crovace A, Lacitignola L, Rossi G, Francioso E. Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon.. Vet Med Int 2010;2010:250978.
    pmc: PMC2859019pubmed: 20445779doi: 10.4061/2010/250978google scholar: lookup
  10. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.. Equine Vet J 2012 Jan;44(1):25-32.
    pubmed: 21615465doi: 10.1111/j.2042-3306.2011.00363.xgoogle scholar: lookup
  11. Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F, Carlucci F, Petrini M. Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses.. Tissue Eng 2007 Dec;13(12):2949-55.
    pubmed: 17919069doi: 10.1089/ten.2007.0108google scholar: lookup
  12. Schnabel LV, Lynch ME, van der Meulen MC, Yeager AE, Kornatowski MA, Nixon AJ. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons.. J Orthop Res 2009 Oct;27(10):1392-8.
    pubmed: 19350658doi: 10.1002/jor.20887google scholar: lookup
  13. Smith RK. Mesenchymal stem cell therapy for equine tendinopathy.. Disabil Rehabil 2008;30(20-22):1752-8.
    pubmed: 18608378doi: 10.1080/09638280701788241google scholar: lookup
  14. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
    pubmed: 24433318doi: 10.1111/j.1532-950X.2014.12100.xgoogle scholar: lookup
  15. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 2009 Dec;27(12):1675-80.
    pubmed: 19544397doi: 10.1002/jor.20933google scholar: lookup
  16. Sole A, Spriet M, Galuppo LD, Padgett KA, Borjesson DL, Wisner ER, Brosnan RJ, Vidal MA. Scintigraphic evaluation of intra-arterial and intravenous regional limb perfusion of allogeneic bone marrow-derived mesenchymal stem cells in the normal equine distal limb using (99m) Tc-HMPAO.. Equine Vet J 2012 Sep;44(5):594-9.
    pubmed: 22212017doi: 10.1111/j.2042-3306.2011.00530.xgoogle scholar: lookup
  17. Tol M, Akar AR, Durdu S, Ayyildiz E, Ilhan O. Comparison of different needle diameters and flow rates on bone marrow mononuclear stem cell viability: an ex vivo experimental study.. Cytotherapy 2008;10(1):98-9.
    pubmed: 18202979doi: 10.1080/14653240701762356google scholar: lookup
  18. Walker PA, Jimenez F, Gerber MH, Aroom KR, Shah SK, Harting MT, Gill BS, Savitz SI, Cox CS Jr. Effect of needle diameter and flow rate on rat and human mesenchymal stromal cell characterization and viability.. Tissue Eng Part C Methods 2010 Oct;16(5):989-97.
    pmc: PMC2943405pubmed: 20001789doi: 10.1089/ten.TEC.2009.0423google scholar: lookup
  19. Garvican ER, Cree S, Bull L, Smith RK, Dudhia J. Viability of equine mesenchymal stem cells during transport and implantation.. Stem Cell Res Ther 2014 Aug 8;5(4):94.
    pmc: PMC4247703pubmed: 25107289doi: 10.1186/scrt483google scholar: lookup
  20. Fortier LA, Nixon AJ, Lust G. Phenotypic expression of equine articular chondrocytes grown in three-dimensional cultures supplemented with supraphysiologic concentrations of insulin-like growth factor-1.. Am J Vet Res 2002 Feb;63(2):301-5.
    pubmed: 11843134doi: 10.2460/ajvr.2002.63.301google scholar: lookup

Citations

This article has been cited 8 times.
  1. Awonusi O, Harbin ZJ, Brookes S, Zhang L, Kaefer S, Morrison RA, Newman S, Voytik-Harbin S, Halum S. Impact of Needle Selection on Survival of Muscle-Derived Cells When Used for Laryngeal Injections.. J Cell Sci Ther 2023;14(1).
    pubmed: 37250272
  2. de Souza JB, Rosa GDS, Rossi MC, Stievani FC, Pfeifer JPH, Krieck AMT, Bovolato ALC, Fonseca-Alves CE, Borrás VA, Alves ALG. In Vitro Biological Performance of Alginate Hydrogel Capsules for Stem Cell Delivery.. Front Bioeng Biotechnol 2021;9:674581.
    doi: 10.3389/fbioe.2021.674581pubmed: 34513806google scholar: lookup
  3. Linzenbold W, Fech A, Hofmann M, Aicher WK, Enderle MD. Novel Techniques to Improve Precise Cell Injection.. Int J Mol Sci 2021 Jun 14;22(12).
    doi: 10.3390/ijms22126367pubmed: 34198683google scholar: lookup
  4. Bertoni L, Jacquet-Guibon S, Branly T, Desancé M, Legendre F, Melin M, Rivory P, Hartmann DJ, Schmutz A, Denoix JM, Demoor M, Audigié F, Galéra P. Evaluation of Allogeneic Bone-Marrow-Derived and Umbilical Cord Blood-Derived Mesenchymal Stem Cells to Prevent the Development of Osteoarthritis in An Equine Model.. Int J Mol Sci 2021 Mar 2;22(5).
    doi: 10.3390/ijms22052499pubmed: 33801461google scholar: lookup
  5. Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, François I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.. PLoS One 2019;14(8):e0221317.
    doi: 10.1371/journal.pone.0221317pubmed: 31465445google scholar: lookup
  6. Bertoni L, Branly T, Jacquet S, Desancé M, Desquilbet L, Rivory P, Hartmann DJ, Denoix JM, Audigié F, Galéra P, Demoor M. Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses.. Stem Cells Int 2019;2019:9431894.
    doi: 10.1155/2019/9431894pubmed: 31191689google scholar: lookup
  7. Bogers SH. Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.. Front Vet Sci 2018;5:70.
    doi: 10.3389/fvets.2018.00070pubmed: 29713634google scholar: lookup
  8. Chen X, Foote AG, Thibeault SL. Cell density, dimethylsulfoxide concentration and needle gauge affect hydrogel-induced bone marrow mesenchymal stromal cell viability.. Cytotherapy 2017 Dec;19(12):1522-1528.
    doi: 10.1016/j.jcyt.2017.08.016pubmed: 28986174google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.